Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360° synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of SLE
3.2.1.2 Advancements in treatment options
3.2.1.3 Increased government funding and support for research on autoimmune diseases
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of treatment
3.2.2.2 Limited awareness and diagnosis
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Immunosuppressants
5.3 Corticosteroids
5.4 Biologics
5.5 Antimalarials
5.6 NSAIDs
Chapter 6 Market Estimates and Forecast, By Gender, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Female
6.3 Male
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Intravenous
7.4 Subcutaneous
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Other distribution channels
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Anthera Pharmaceuticals, Inc.
10.2 Aurinia Pharmaceuticals, Inc.
10.3 AstraZeneca
10.4 Biogen
10.5 Bristol-Myers Squibb Company
10.6 Eli Lilly and Company
10.7 F. Hoffmann-La Roche Ltd.
10.8 GSK plc.
10.9 ImmuPharma PLC
10.10 Johnson & Johnson Services, Inc.
10.11 Merck & Co., Inc.
10.12 Novartis AG
10.13 Pfizer, Inc.
10.14 Sanofi SA
10.15 Sandoz International GmbH
